Logo

Lilly Entered into a Collaboration with Evotec to Develop Therapies for Diabetes and Chronic Kidney Diseases

Share this

Lilly Entered into a Collaboration with Evotec to Develop Therapies for Diabetes and Chronic Kidney Diseases

Shots:

  • Evotec to receive an up front with the total deal value of~$1B & will be eligible to receive success-based discovery development, regulatory and commercial milestone of ~$180M/program along with royalties on net sales of any products
  • Lilly gets the right to select up to five programs developed from the collaboration and be responsible for the development, clinical validation, and commercialization. Evotec will lead the discovery of drug candidates
  • The collaboration will use Evotec’s metabolic expertise, kidney disease patient database along with integrated data-driven drug discovery and development platforms to develop therapies for diabetes and kidney diseases

Ref: Evotec | Image: Wikipedia

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions